Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir (RAL) and elvitegravir (EVG), DTG shows a limited cross-resistance profile. More interestingly, clinica...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2015-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|